Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The most common cause of death in patients with NAFLD(Nonalcoholic Fatty Liver Disease) is CAD(Coronary Artery Disease). NAFLD patients have 65% more mortality than general population. The aim of the investigators study is to diagnose early coronary artery disease in NAFLD patient by measuring of PLA2. The investigators expect that PLA2 will higher in patients with patients with combination of CAD, unstable plaque and NAFLD.
Background: The most common cause of death in patients with NAFLD(Nonalcoholic Fatty Liver Disease) is CAD(Coronary Artery Disease). NAFLD patients have 65% more mortality than general population. The aim of our study is to diagnose early coronary artery disease in NAFLD patient by measuring of PLA2.
Methods: 60 patients with chest pain and low to intermediate risk for coronary events will undergo Cardiac CT and blood test measurement of enzyme PLA2, markers of inflammation: CRP, MDA(Malondialdehide), Paraoxonase, FFA(Free Fatty Acids), TG(Triglycerids) will performed.
CAD is defined as a stenosis of more than 50% in at least one major coronary artery, unstable plaque defined as low attenuated plaque <30HU and fatty liver defined as difference in liver and spleen attenuation value -10HU by using CT.
Expected results : we expect that PLA2 will higher in patients with patients with combination of CAD, unstable plaque and NAFLD.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Inclusion Criteria:
Intermediate Risk patients for having significant CAD is deļ¬ned as:
Exclusion Criteria:
Acute coronary syndrome presentation:
Cardiac troponin elevation.
Chest pain in combination with positive tests for myocardial ischemia
Hemodynamic instability on presentation.
Inability to write inform consent.
Age <18 years.
Participation in an investigational study within the previous 30days.
Not provided
Not provided
Not provided
Intermediate Risk patients for having significant CAD is deļ¬ned as:
a - chest pain or dyspnea in the presence of negative stress tests; b - the absence of chest pain but positive stress tests; c - the absence of chest pain and of positive stress tests but intermittent arrhythmias.
Age <18 years.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nimer Assy, MD | ZIV MEDICAL CENTER, SAFED ISRAEL | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ziv medical center liver unit | Safed, Israel | 13100 | Israel |
Not provided
| ID | Term |
|---|---|
| D065626 | Non-alcoholic Fatty Liver Disease |
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D005234 | Fatty Liver |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D003327 | Coronary Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D017202 |
| Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |